Sobi Strengthens Gout Treatment Options with Arthrosi Therapeutics Acquisition Sobi has finalized its acquisition of Arthrosi Therapeutics, enhancing its portfolio with a promising gout treatment, pozdeutinurad.

Sobi Strengthens Gout Treatment Options with Arthrosi Therapeutics Acquisition #Sweden #Stockholm #Sobi #gout #Arthrosi

Sobi Announces Acquisition of Arthrosi Therapeutics to Enhance Gout Treatment Pipeline Sobi's acquisition of Arthrosi Therapeutics aims to boost innovation in gout treatments, particularly with the introduction of pozdeutinurad, a new oral therapy.

Sobi Announces Acquisition of Arthrosi Therapeutics to Enhance Gout Treatment Pipeline #None #Sobi #pozdeutinurad #Arthrosi

Viva Biotech's Arthrosi Enters $1.5 Billion Acquisition with Sobi Viva Biotech's Arthrosi Therapeutics has signed an acquisition agreement with Sobi worth up to $1.5 billion, enhancing gout treatment options.

Viva Biotech's Arthrosi Enters $1.5 Billion Acquisition with Sobi #Sweden #Stockholm #Sobi #Viva_Biotech #Arthrosi

Viva Biotech's Arthrosi Enters $1.5 Billion Acquisition Deal with Sobi Viva Biotech's incubated company, Arthrosi, has made headlines with its significant acquisition agreement with Sobi worth up to $1.5 billion.

Viva Biotech's Arthrosi Enters $1.5 Billion Acquisition Deal with Sobi #None #Sobi #Viva_Biotech #Arthrosi

Arthrosi's $153 Million Series E Financing: A Milestone in Gout Treatment Development Arthrosi Therapeutics has successfully closed a $153 million Series E financing to advance pozdeutinurad, a next-gen treatment for gout.

Arthrosi's $153 Million Series E Financing: A Milestone in Gout Treatment Development #United_States #San_Diego #Gout_Treatment #pozdeutinurad #Arthrosi

Arthrosi Shares Promising Results for Pozdeutinurad at EULAR 2025, Highlighting Long-Term Efficacy Arthrosi Therapeutics reveals significant long-term safety and efficacy data for pozdeutinurad in gout treatment at the EULAR 2025 Congress. Researchers confirm its efficacy and tolerability.

Arthrosi Shares Promising Results for Pozdeutinurad at EULAR 2025, Highlighting Long-Term Efficacy #United_States #San_Diego #Gout_Treatment #pozdeutinurad #Arthrosi